Trial · NCT00230802
Thyroid Hormone Dose Adjustment in Pregnancy
NCT00230802, Not applicable, Completed, Brigham and Women's Hospital; results first posted 2016-12-23
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Thyroid Hormone Dose Adjustment in Pregnancy. Trials, record NCT00230802. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00230802
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Thyroid Hormone Dose Adjustment in Pregnancy
- NCT number
- NCT00230802
- Status
- Completed
- Phases
- Not applicable
- Enrollment
- 48 participants, actual
- Lead sponsor
- Brigham and Women's Hospital
- Conditions
- Pregnancy, Hypothyroidism
- Interventions
- Anticipatory dose increase of levothyroxine, levothyroxine, levothyroxine
- First posted
- 2005-10-03
- Last updated
- 2016-12-23
- Results first posted
- 2016-12-23
Source ClinicalTrials.gov
Registered outcomes3
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Proportion of Patients in Each Treatment Arm Euthyroid Through Gestation | 9 months | The proportion of patients in each treatment arm euthyroid through gestation |
| Secondary | the Participants in Each Arm Who Required Levothyroxine Dose Adjustments (Either Increased or Decreased) Occurred to Maintain a Euthyroid State | 9 months | |
| Secondary | Proportion of Subjects With Abnormal Thyroid Stimulating Hormone Values When Following an Every 4 Week Monitoring Schedule During Pregnancy. | 9 months |
Source ClinicalTrials.gov
Outcomes3
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Proportion of Patients in Each Treatment Arm Euthyroid Through Gestation | 9 months | proportion of patients in each treatment arm euthyroid through gestation | participants | NUMBER |
| SECONDARY | the Participants in Each Arm Who Required Levothyroxine Dose Adjustments (Either Increased or Decreased) Occurred to Maintain a Euthyroid State | 9 months | participants | NUMBER | |
| SECONDARY | Proportion of Subjects With Abnormal Thyroid Stimulating Hormone Values When Following an Every 4 Week Monitoring Schedule During Pregnancy. | 9 months | participants | NUMBER |
Source ClinicalTrials.gov
Results by group6
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Proportion of Patients in Each Treatment Arm Euthyroid Through Gestation | 2 Tablet Increase | 24 | participants | ||
| Proportion of Patients in Each Treatment Arm Euthyroid Through Gestation | 3 Tablet Increase | 21 | participants | ||
| the Participants in Each Arm Who Required Levothyroxine Dose Adjustments (Either Increased or Decreased) Occurred to Maintain a Euthyroid State | 2 Tablet Increase | 10 | participants | ||
| the Participants in Each Arm Who Required Levothyroxine Dose Adjustments (Either Increased or Decreased) Occurred to Maintain a Euthyroid State | 3 Tablet Increase | 16 | participants | ||
| Proportion of Subjects With Abnormal Thyroid Stimulating Hormone Values When Following an Every 4 Week Monitoring Schedule During Pregnancy. | 2 Tablet Increase | 25 | participants | ||
| Proportion of Subjects With Abnormal Thyroid Stimulating Hormone Values When Following an Every 4 Week Monitoring Schedule During Pregnancy. | 3 Tablet Increase | 23 | participants |
Source ClinicalTrials.gov
Participant flow6
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | 2 Tablet Increase | 25 | |
| Overall Study | STARTED | 3 Tablet Increase | 23 | |
| Overall Study | COMPLETED | 2 Tablet Increase | 25 | |
| Overall Study | COMPLETED | 3 Tablet Increase | 23 | |
| Overall Study | NOT COMPLETED | 2 Tablet Increase | 0 | |
| Overall Study | NOT COMPLETED | 3 Tablet Increase | 0 |
Source ClinicalTrials.gov
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals6
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | 2 Tablet Increase | ||
| Total, all-cause mortality | 3 Tablet Increase | ||
| Total, other adverse events | 2 Tablet Increase | 0 | 25 |
| Total, other adverse events | 3 Tablet Increase | 0 | 23 |
| Total, serious adverse events | 2 Tablet Increase | 0 | 25 |
| Total, serious adverse events | 3 Tablet Increase | 0 | 23 |
Source ClinicalTrials.gov
Papers1
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as |
|---|---|
| 20463094 | RESULT |
Source PubMed
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons4
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|---|
| 2 Tablet Increase vs 3 Tablet Increase: the Participants in Each Arm Who Required Levothyroxine Dose Adjustments (Either Increased or Decreased) Occurred to Maintain a Euthyroid State | Trial comparisons |
| 2 Tablet Increase vs 3 Tablet Increase: Proportion of Subjects With Abnormal Thyroid Stimulating Hormone Values When Following an Every 4 Week Monitoring Schedule During Pregnancy. | Trial comparisons |
| 2 Tablet Increase vs 3 Tablet Increase: Proportion of Patients in Each Treatment Arm Euthyroid Through Gestation | Trial comparisons |
| 2 Tablet Increase vs 3 Tablet Increase: serious adverse events | Trial comparisons |
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT00230802
GET https://conductscience.org/api/trials/v1/NCT00230802/registered